

Form Approved OMB No. 0920-0666 Exp. Date: ... www.cdc.gov/nhsn

Complete this survey as described in the **Dialysis Event Protocol**.

**Instructions:** This survey is only for dialysis centers that **do not** provide in-center hemodialysis. If your center performs in-center hemodialysis, please complete the <u>Outpatient Dialysis Center Practices Survey</u>. Complete one survey per center. Surveys are completed for the current year. It is strongly recommended that the survey is completed in February of each year by someone who works in the center and is familiar with current practices within the center. Complete the survey based on the actual practices at the center, not necessarily the center policy, if there are differences. Please submit your responses to the questions in this survey electronically by logging into your NHSN facility.

	to save as complete	у.			
			*Survey Year:		
	Network #:		,		
A. Dialy	sis Center Information	n			
A.1. Ge					
*1.	What is the ownership	of your dialysis center? (choose on	ie)		
	□ Government	☐ Not for profit	□ For profit		
*2.	What is the location/ho	ospital affiliation of your dialysis cen	ter? (choose one)		
	$\square$ Freestanding	$\square$ Hospital based	$\square$ Freestanding but owned by a	a hospital	
*3.	Is your facility accredit a. If yes, specify (	red by an organization other than CN choose one)	MS?	$_{\square}$ Yes	$_{\square}$ No
		☐ National Dialysis Accreditation Commission (NDAC)	for Health Care (ACHC)	□ Other (sp	ecify)
*4.	• • • • • • • • • • • • • • • • • • • •	sis services does your center offer?	(select all that apply)		
	□ Peritoneal dialysis	☐ Home hemodialysis			
	b. What patient popula	ation does your center serve? (selec	t one)		
	$\square$ Adult only	•	☐ Mixed: adult and pediatric		
*5.	Is your center part of a	a group or chain of dialysis centers?		☐ Yes	□ No
		the name of the group or chain?		_	
*6.		imarily responsible for completing th n the homes of patients cared for by		n □ Yes	□ No
*7.		ride dialysis services within long-terr rsing homes or skilled nursing faciliti		☐ Yes	□ No
		many long-term care facilities?			
A.2. Sui	rveillance				
*8.	Which of the following (select all that apply)	infections in your peritoneal dialysis	•	-	
	□ Peritonitis	$\square$ Exit site infection $\sqcap$ Tunn	el infection    Other (specify)	)	
*9.	Which of the following (select all that apply)	events in your home hemodialysis p			
	☐ Bloodstream infect	3	ent $\square$ Other (spec	cify)	
	<ul><li>Vascular access sit infection</li></ul>	e ☐ Air embolism ☐ Catheter breakage or blood	lling congration		
Assurance		ily provided information obtained in this surveillance	•	individual or institu	ution is
collected w	ith a guarantee that it will be held	in strict confidence, will be used only for the purpos accordance with Sections 304, 306 and 308(d) of th	ses stated, and will not otherwise be disclosed	or released withou	
data source person is n any other a	es, gathering and maintaining the outrequired to respond to a collection	formation is estimated to average 25 minutes per redata needed, and completing and reviewing the colion of information unless it displays a currently valicion, including suggestions for reducing this burden	lection of information. An agency may not cond d OMB control number. Send comments regard	duct or sponsor, an ling this burden es	nd a timate or

CDC 57.507 (Back) Rev 0, v8.6



A 2 C.	weillenes (continued)		
	urveillance (continued)		
*10.	If a patient from your center was hospitalized, how often is your center able to determine if a bloodstream		
	infection contributed to their hospital admission?  □ Always □ Often □ Sometimes		
	□ Rarely □ Never □ N/A – not pursued		
	·		
*11.	How often is your center able to obtain a patient's microbiology lab records from a hospitalization?  □ Always □ Often □ Sometimes		
	☐ Rarely ☐ Never ☐ N/A – not pursued		
	e respond to the following questions based on information from your center for the <u>first week of February</u> s to current or most recent February relative to current date).		
B. Pati	ient and staff census		
*12.	Was your center operational during the first week of February? ☐ Yes ☐ No		
*13.	How many dialysis <b>PATIENTS</b> were assigned to your center during the first week of February?		
	Of these, indicate the number who received:		
	a. Peritoneal dialysis:		
	b. Home hemodialysis:		
*14.	How many <b>PATIENT CARE</b> staff (full time, part time, or affiliated with) worked in your center during the first		
14.	week of February? Include only staff who had direct contact with dialysis patients or equipment:		
	Of these, how many were in each of the following categories?		
	a. Nurse/nurse assistant:		
	h Dickeis nationt care technician:		
	a Distrois hismadical technician:		
	d. Social worker:		
	e. Dietitian:		
	f. Physicians/physician assistant:		
	g. Nurse practitioner:		
	h. Other:		
C. Vac	cines		
+1 -	Of the position call disharing actionts accorded in according 10c hours are according		
*15.	Of the <u>peritoneal dialysis patients</u> counted in question 13a, how many received:		
	a. A complete series of hepatitis B vaccine (ever)?		
	b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?		
	c. At least one dose of pneumococcal vaccine (ever)?		
*16.	Of the <u>home hemodialysis patients</u> counted in question 13b, how many received:		
	a. A complete series of hepatitis B vaccine (ever)?		
	b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?		
	c. At least one dose of pneumococcal vaccine (ever)?		
*17.	Of the patient care staff members counted in question 14, how many received:		
17.	a. A complete series of hepatitis B vaccine (ever)?		
	b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?		
*18.	Which type of pneumococcal vaccine does your center offer to <b>patients</b> ? (choose one)		
	□ Polysaccharide (i.e., PPSV23) only		
	☐ Conjugate (e.g., PCV13) only		
	☐ Both polysaccharide & conjugate		
	☐ Neither offered		



D. Scre	ening
*19.	Does your center routinely screen patients for <b>hepatitis B</b> surface antigen (HBsAg) upon initiation of care?
	a. Peritoneal patients $\square$ Yes $\square$ No
	b. Home hemodialysis patients $\ \square$ Yes $\ \square$ No
*20.	Does your center routinely screen patients for <b>hepatitis C</b> antibody (anti-HCV) upon initiation of care?
	a. Peritoneal patients $\square$ Yes $\square$ No
	b. Home hemodialysis patients $\ \square$ Yes $\ \square$ No
*21.	Does your center routinely screen patients for latent tuberculosis infection (LTBI) upon initiation of care?
	a. Peritoneal patients $\square$ Yes $\square$ No
	b. Home hemodialysis patients $\square$ Yes $\square$ No
*22.	If your center does routinely screen patients for <b>latent tuberculosis infections (LTBI)</b> , what method is used? (select all that apply)
	a. Peritoneal patients $\Box$ Tuberculin Skin Test (TST) $\Box$ Blood Test $\Box$ Other (specify)
	b. Home hemodialysis patients $\ \square$ Tuberculin Skin Test (TST) $\ \square$ Blood Test $\ \square$ Other (specify)
E.2 Pre	vention Activities
*23.	Is your center actively participating in any of the following prevention initiatives (select all that apply):
	☐ CDC Making Dialysis Safer for Patients Coalition – facility-level participation
	☐ CDC Making Dialysis Safer for Patients Coalition – corporate- or other organization-level participation
	<ul> <li>The Standardizing Care to improve Outcomes in Pediatric End Stage Renal Disease (SCOPE)</li> <li>Collaborative Peritoneal Dialysis Catheter-related Infection Project</li> </ul>
	☐ SCOPE Collaborative Hemodialysis Access-related Infection Project
	$\square$ None of the above
*24.	In the past year, has your center's medical director participated in a leadership or educational — Yes — No activity as part of the American Society of Nephrology's (ASN) Nephrologists Transforming Dialysis Safety (NTDS) Initiative?
F. Perit	oneal Dialysis Catheters
*25.	For <b>peritoneal dialysis catheters</b> , is antimicrobial ointment routinely applied to the exit site
	<ul><li>a. If yes, what type of ointment is most commonly used? (select one)</li><li>Gentamicin</li><li>Bacitracin/polymyxin B (e.g., Polysporin®)</li></ul>
	☐ Mupirocin ☐ Bacitracin/polymyxin B (triple antibiotic)
	☐ Povidone-iodine ☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple)
	☐ Other, specify:
G Vaso	cular Access
*26.	eneral Vascular Access Information  Of the home hemodialysis patients from question 13b, how many received dialysis through each of the
20.	following access types during the first week of February?
	a. AV fistula:
	b. AV graft: c. Tunneled central line:
	d. Nontunneled central line:
	e. Other vascular access device (e.g., HeRO®):
G.2. Art	teriovenous (AV) Fistulas or Grafts
*27.	Before prepping the fistula or graft site for rope-ladder cannulation, what is the site most often <u>cleansed</u> with?
	☐ Soap and water ☐ Other, specify:
	$\square$ Alcohol-based hand rub $\square$ Nothing



G.2. Ar	rteriovenous (AV) Fistulas or Grafts (continued)		
*28.	Before rope-ladder cannulation of a fistula or graft, what is the site most often <u>prepped</u> with? (select the one most commonly used)		
	□ Alcohol		
	☐ Chlorhexidine without alcohol		
	☐ Chlorhexidine with alcohol (e.g., Chloraprep®, PDI Prevantics®)		
	☐ Povidone-iodine (or tincture of iodine)		
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol		
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol		
	☐ Other, specify:		
	□ Nothing		
	a. What form of this skin antiseptic is used to prep fistula/graft sites?		
	☐ Multiuse bottle (e.g., poured onto gauze)		
	☐ Pre-packaged pad		
	☐ Pre-packaged swabstick/spongestick		
	☐ Other, specify:		
	□ N/A		
*29.	Does your <u>home</u> hemodialysis facility perform buttonhole cannulation?	□ Yes	$\square$ No
	a. Of AV fistula patients from question 26a, how many had buttonhole cannulation?		
	b. When buttonhole cannulation is performed for home hemodialysis patients:		
	i. Who most often performs it?		
	<ul><li>□ Patient (self-cannulation)</li><li>□ Caregiver</li></ul>		
	□ Other specify:		
	ii. Before cannulation, what is the buttonhole site most often prepped with? (select the	e one mos	st
	commonly used)		
	☐ Alcohol		
	<ul> <li>□ Chlorhexidine without alcohol</li> <li>□ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)</li> </ul>		
	□ Povidone-iodine (or tincture of iodine)		
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol		
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol		
	Other, specify:		
	☐ Nothing iii. Is antimicrobial ointment (e.g., mupirocin) routinely used at buttonhole	□ Yes	
	cannulation sites to <b>prevent</b> infection?	□ 162	□ I <b>V</b> O
	·		
G.3. He	emodialysis Catheters		
*30.	Are patients who receive hemodialysis through a central venous catheter permitted in your home	□ Yes	□ No
	hemodialysis program?		
*31.	Before accessing the hemodialysis catheter, what are the <b>catheter hubs</b> most commonly prepped (select the one most commonly used)	with?	
	□ Alcohol		
	☐ Chlorhexidine without alcohol		
	<ul> <li>□ Chlorhexidine with alcohol (e.g., Chloraprep®, PDI Prevantics®)</li> <li>□ Povidone-iodine (or tincture of iodine)</li> </ul>		
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol		
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol		
	□ Other, specify:		
	□ Nothing		



G.3. H	emodialysis Catheters (continued)	
	a. What form of this antiseptic/disinfectant is used to prep the catheter hubs?	
	☐ Multiuse bottle (e.g., poured onto gauze)	
	☐ Pre-packaged swabstick/ spongestick	
	☐ Pre-packaged pad	
	☐ Other, specify:	
	□ N/A	
*32.	Are catheter hubs routinely scrubbed after the cap is removed and before accessing the catheter	□ No
	(or before accessing the catheter via a needleless connector device, if one is used)?	
*33.	When the catheter dressing is changed, what is the exit site (i.e., place where the catheter enters the skin) memory prepared with? (select the one most commonly used)	ost
	□ Alcohol	
	☐ Chlorhexidine without alcohol	
	☐ Chlorhexidine with alcohol (e.g., Chloraprep®, PDI Prevantics®)	
	☐ Povidone-iodine (or tincture of iodine)	
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol	
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol	
	□ Other, specify:	
	□ Nothing	
	a. What form of this antiseptic/disinfectant is used at the exit site?	
	☐ Multiuse bottle (e.g., poured onto gauze)	
	☐ Pre-packaged swabstick/spongestick	
	☐ Pre-packaged pad	
	☐ Other, specify:	
*34.	For <b>hemodialysis catheters</b> , is antimicrobial ointment routinely applied to the exit site during dressing chan-	ne?
01.	☐ Yes ☐ No ☐ N/A — chlorhexidine-impregnated dressing is routinely used	go.
	a. If yes, what type of ointment is most commonly used? (select one)	
	☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple) ☐ Gentamicin	
	☐ Bacitracin/polymyxin B (e.g., Polysporin®) ☐ Mupirocin	
	☐ Bacitracin/neomycin/polymyxin B (triple antibiotic) ☐ Povidone-iodine	
	☐ Other, specify:	
*35.	Are antimicrobial lock solutions used to <b>prevent</b> hemodialysis catheter infections?	
	$\Box$ Yes, for all catheter patients $\Box$ Yes, for some catheter patients $\Box$ No	
	a. If yes, which lock solution is most commonly used? (select one)	
	□ Sodium citrate □ Taurolidine	
	☐ Gentamicin ☐ Ethanol	
	☐ Vancomycin ☐ Multi-component lock solution or other, specify:	
*36.	Are needleless closed connector devices (e.g., Tego®, Q-Syte™) used on your patients' ☐ Yes hemodialysis catheters?	□No
*37.	Are any of the following routinely used for your hemodialysis catheter patients? (select all that apply)	
0	Chlorhexidine dressing (e.g., Biopatch®, Tegaderm™ CHG)	
	Other antimicrobial dressing (e.g., silver-impregnated)	
	Antiseptic-impregnated catheter cap/port protector:	
	3M™ Curos™ Disinfecting Port Protectors	П
	ClearGuard® HD end caps	П
	Antimicrobial-impregnated hemodialysis catheters	
	Antimicrobia-impregnated hemodialysis catheters	



Form Approved OMB No. 0920-0666 Exp. Date: 11/30/2019 www.cdc.gov/nhsn

6



G.3. H	emodialysis Catheters (continued)
*38.	Does your center provide hemodialysis catheter patients with supplies to allow for changing catheter dressings at home?
	$\square$ Yes, routinely for all or most $\square$ Yes, only for select patients with a $\square$ No patients with a catheter catheter
*39.	Does your center educate patients with hemodialysis catheters on how to shower with the catheter? (select the best response)
	☐ Yes, routinely for all or most patients with a catheter ☐ No, patients with hemodialysis catheters are instructed against showering
	☐ Yes, only for select patients with a catheter ☐ No, education and instructions are not provided on this topic
	a. Does your center provide hemodialysis catheter patients with a protective catheter cover (e.g., Shower Shield®, Cath Dry™) to allow them to shower?
	<ul> <li>☐ Yes, routinely for all or most patients with a catheter</li> <li>☐ Yes, only for select patients with a catheter</li> <li>☐ No</li> </ul>
Comm	ents:
Di- 1	
וטואכומון	er: Use of trade names and commercial sources is for identification only and does not imply endorsement.